[go: up one dir, main page]

SG11201908054XA - Methods and compositions for treating cancers using antisense - Google Patents

Methods and compositions for treating cancers using antisense

Info

Publication number
SG11201908054XA
SG11201908054XA SG11201908054XA SG11201908054XA SG11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA
Authority
SG
Singapore
Prior art keywords
international
compositions
methods
antisense
philadelphia
Prior art date
Application number
SG11201908054XA
Inventor
David Andrews
Douglas Hooper
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of SG11201908054XA publication Critical patent/SG11201908054XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)

Abstract

Title: METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE (57) : The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF- IR). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma. PMMA hemirings FIG. 1A W O 20 18/ 1655 28 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT 0111111010 0111 °nolo VIII ono iflo oimIE (10) International Publication Number WO 2018/165528 Al (51) International Patent Classification: C12N 5/02 (2006.01) Cl 2N 15/113 (2010.01) C12N 5/10 (2006.01) Cl 2P 19/34 (2006.01) C12N 15/09 (2006.01) CO7H 21/04 (2006.01) C12N 15/11 (2006.01) C12Q 1/68 (2018.01) C12N 15/52 (2006.01) (21) International Application Number: PCT/US2018/021706 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,003 09 March 2017 (09.03.2017) US 62/629,972 13 February 2018 (13.02.2018) US (71) Applicant: THOMAS JEFFERSON UNIVERSITY [US/US]; 901 Walnut Street, Innovation Pillar, 11th Floor, Philadelphia, PA 19107 (US). (72) Inventors: ANDREWS, David, W.; 8882 Norwood Av- enue, Philadelphia, PA 19118 (US). HOOPER, Douglas, C.; 2 Oregon Trail, Medford, NJ 08055 (US). (74) Agent: VOS STRACHE, Kyle; Cozen O'Connor, 1650 Market Street, One Liberty Place, Suite 2800, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] WO 2018/165528 Al MIDEDIM01101 DIDIREIE311111111111111111111111101111111111111111111 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201908054XA 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense SG11201908054XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469003P 2017-03-09 2017-03-09
US201862629972P 2018-02-13 2018-02-13
PCT/US2018/021706 WO2018165528A1 (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Publications (1)

Publication Number Publication Date
SG11201908054XA true SG11201908054XA (en) 2019-09-27

Family

ID=62838976

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202109912X SG10202109912XA (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense
SG11201908054XA SG11201908054XA (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202109912X SG10202109912XA (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Country Status (14)

Country Link
US (5) US10357509B2 (en)
EP (2) EP3592841B1 (en)
JP (2) JP2020510021A (en)
KR (2) KR20240116561A (en)
CN (2) CN110832068A (en)
AU (2) AU2018230458B2 (en)
BR (1) BR112019018555A2 (en)
CA (1) CA3054662A1 (en)
IL (2) IL316679A (en)
MX (2) MX2019010725A (en)
NZ (1) NZ756820A (en)
RU (1) RU2766457C2 (en)
SG (2) SG10202109912XA (en)
WO (1) WO2018165528A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016246134B2 (en) 2015-04-10 2022-04-21 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
CA3001005A1 (en) 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
SG11201901667TA (en) 2016-09-16 2019-03-28 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
WO2018165528A1 (en) 2017-03-09 2018-09-13 Thomas Jefferson University Methods and compositions for treating cancers using antisense
CA3058486A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for bcl2 inhibition
BR112020015028A2 (en) * 2018-01-24 2020-12-29 Thomas Jefferson University BIODIFUSION CHAMBER
AU2019347999A1 (en) * 2018-09-26 2021-04-22 Thomas Jefferson University Neoantigen compositions; and methods of preparation and use thereof
WO2020092684A1 (en) * 2018-11-02 2020-05-07 Thomas Jefferson University Methods and compositions for treating breast cancer using antisense
US20210403918A1 (en) * 2018-11-02 2021-12-30 Thomas Jefferson University Methods and compositions for treating hepatocellular carcinoma using antisense
AU2020244865A1 (en) * 2019-03-28 2021-10-21 Thomas Jefferson University Methods for treating cancers using antisense
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
WO1994022486A1 (en) 1993-03-26 1994-10-13 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6541036B1 (en) * 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
JP2002522506A (en) * 1998-08-13 2002-07-23 トーマス・ジェファーソン・ユニバーシティ Treatment of tumors with oligonucleotides directed against the insulin-like growth factor-I receptor
US6144553A (en) 1998-09-09 2000-11-07 Sun Microsystems, Inc. Refrigeration cooled disk storage assembly
US7037335B2 (en) 2002-11-19 2006-05-02 Eagle Vision, Inc. Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma
DK1597366T3 (en) 2003-02-11 2013-02-25 Antisense Therapeutics Ltd Modulation of expression of insulin-like growth factor receptor I
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2447400A1 (en) * 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
KR101913232B1 (en) * 2010-10-27 2018-10-30 큐알엔에이, 인크. Treatment of interferon-related developmental regulator 1(ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
JP6749239B2 (en) 2013-09-24 2020-09-02 ガイナー ライフ サイエンシズ，インク． Cell implant gas treatment system
US9872674B2 (en) * 2014-05-07 2018-01-23 Boehringer Laboratories Inc. Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure
AU2016246134B2 (en) 2015-04-10 2022-04-21 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
EP3900653B1 (en) 2015-04-23 2024-07-24 Applied Medical Resources Corporation Systems for tissue removal
CA3001005A1 (en) 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
WO2018165528A1 (en) 2017-03-09 2018-09-13 Thomas Jefferson University Methods and compositions for treating cancers using antisense
BR112020015028A2 (en) 2018-01-24 2020-12-29 Thomas Jefferson University BIODIFUSION CHAMBER

Also Published As

Publication number Publication date
AU2018230458B2 (en) 2024-11-21
EP3592841B1 (en) 2024-02-14
RU2766457C2 (en) 2022-03-15
AU2024227517A1 (en) 2024-11-14
BR112019018555A2 (en) 2020-04-14
IL268872A (en) 2019-10-31
AU2018230458A1 (en) 2019-09-05
US20180201939A1 (en) 2018-07-19
JP2020510021A (en) 2020-04-02
CN110832068A (en) 2020-02-21
IL268872B1 (en) 2024-12-01
KR20240116561A (en) 2024-07-29
US11801259B2 (en) 2023-10-31
JP2023081916A (en) 2023-06-13
EP3592841A1 (en) 2020-01-15
EP4378531A2 (en) 2024-06-05
RU2019130010A (en) 2021-04-10
CN118750590A (en) 2024-10-11
NZ756820A (en) 2022-08-26
CA3054662A1 (en) 2018-09-13
KR20190140440A (en) 2019-12-19
US20180256625A1 (en) 2018-09-13
MX2024008496A (en) 2024-07-15
US10357509B2 (en) 2019-07-23
US20240100078A1 (en) 2024-03-28
EP3592841A4 (en) 2021-01-06
IL316679A (en) 2024-12-01
MX2019010725A (en) 2020-02-10
RU2019130010A3 (en) 2021-07-05
EP4378531A3 (en) 2024-09-04
US20190365794A1 (en) 2019-12-05
JP7656350B2 (en) 2025-04-03
US20210060055A1 (en) 2021-03-04
US10772904B2 (en) 2020-09-15
SG10202109912XA (en) 2021-10-28
IL268872B2 (en) 2025-04-01
WO2018165528A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
SG11201908054XA (en) Methods and compositions for treating cancers using antisense
SG11201907846VA (en) Therapeutic rna
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201900699QA (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties
SG11201805872SA (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201900028VA (en) Crispr/cas9-based compositions and methods for treating cancer
SG11201806340YA (en) Zika virus vaccine
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201811457QA (en) Methods and devices for valve clip excision
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201901841TA (en) Targeting ligands
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201903032SA (en) Methods and compositions related to nk cell and anti-pdl1 cancer therapies
SG11201808125RA (en) Methods for solid tumor treatment
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201901411VA (en) Conditionally active polypeptides and methods of generating them
SG11201900361RA (en) Methods of treating prostate cancer